Af­ter decades in Big Phar­ma, Kel­ly Page heads to 'growth stage'; Al­lied with No­var­tis, Bi­cy­cle se­lects de­vel­op­ment chief

Fol­low­ing a decades-long ca­reer in Big Phar­ma, Kel­ly Page want­ed to use her re­search and com­mer­cial ex­pe­ri­ence to help a small com­pa­ny grow.

Last Tues­day, she start­ed at Arv­inas, a Pfiz­er-part­nered biotech look­ing to har­ness the body’s pro­tein dis­pos­al sys­tem to de­grade dis­ease-caus­ing pro­teins. She has tak­en the role of se­nior VP and glob­al head of on­col­o­gy strat­e­gy and pro­gram lead­er­ship, a field that’s mo­ti­vat­ed her per­son­al­ly since three close rel­a­tives were di­ag­nosed with lym­phoma in 1999.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN